Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 147
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
Chibuzo Sampson, Qiuping Wang, Wuxiyar Otkur, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 3
Open Access | Times Cited: 66
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization
Martin P. Schwalm, Andreas Krämer, Anja Dölle, et al.
Cell chemical biology (2023) Vol. 30, Iss. 7, pp. 753-765.e8
Open Access | Times Cited: 46
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
Jiahong Zheng, Bang Li, Yingqi Wu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8407-8427
Closed Access | Times Cited: 35
Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy
Ni‐Yuan Zhang, Da‐Yong Hou, Xingjie Hu, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 37
Closed Access | Times Cited: 35
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Stimuli‐Responsive PROTACs for Controlled Protein Degradation
Keli An, Xuqian Deng, Hongli Chi, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 39
Closed Access | Times Cited: 31
Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
Ruoxi Sang, Renming Fan, Aohua Deng, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8464-8483
Closed Access | Times Cited: 28
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Research in the Field of Drug Design and Development
Grażyna Biała, Ewa Kędzierska, Marta Kruk-Słomka, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1283-1283
Open Access | Times Cited: 27
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy
Jing Huang, Zhuo Yao, Bowen Li, et al.
Journal of Controlled Release (2023) Vol. 361, pp. 270-279
Closed Access | Times Cited: 25
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
Gang Xue, Jianing Xie, Matthias Hinterndorfer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Xiang Li, Qian Liu, Xin Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1700-1711
Closed Access | Times Cited: 23
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, et al.
Molecular Diversity (2023) Vol. 28, Iss. 1, pp. 309-333
Open Access | Times Cited: 22
Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation
Yuhui Jin, Jing Fan, Ruyan Wang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 13, pp. 7218-7229
Closed Access | Times Cited: 22
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 13
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2
Deborah Grifagni, Elena Lenci, Alessia De Santis, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 2, pp. 250-257
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top